Clopidogrel Less Effective in Patients with Diabetes

Published Online: Friday, October 5, 2012
Follow Pharmacy_Times:
Patients with diabetes have a significantly diminished relative effectiveness of platelet inhibition with clopidogrel (Plavix) following myocardial infarction when compared with patients without diabetes.

Scientists led by Charlotte Andersson, MD, PhD, of Gentofte Hospital in Hellerup, Denmark, analyzed 58,851 patients who were hospitalized with incident heart attack, 12% of whom had diabetes, and 60% of whom were treated with clopidogrel. They found that nondiabetic clopidogrel users achieved a significant 23% reduction in cardiovascular mortality, whereas patients with diabetes only achieved a nonsignificant 7% reduction in risk.

In an editorial accompanying the September 5, 2012, article in the Journal of the American Medical Association, Deepak Bhatt, MD, MPH, noted that the reason diabetics do not benefit from clopidogrel as much as other patients is that compared with nondiabetics, diabetics with coronary artery disease have heightened platelet reactivity.

Despite its lower efficacy in preventing secondary heart attack, those patients with diabetes who took clopidogrel had lower crude incidence rates of all-cause mortality than those who were not taking the drug, and authors of the study maintain that clopidogrel may still be worthwhile for patients with diabetes.

Related Articles
Children infected with enterovirus have a 48% increased risk of developing type 1 diabetes.
Even though smoking can exacerbate respiratory conditions and limit the efficacy of their treatment, patients often purchase cigarettes while filling prescriptions for asthma or antihypertensive drugs at pharmacies.
Safeway Pharmacy Offers an Invitation to Individuals with Passion to be a Part of the Community Pharmacy Transformation
Many cardiologists and pharmacists are concerned about clopidogrel, especially when it is prescribed for patients with diabetes.
Latest Issues
$auto_registration$